Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Wednesday 19 September, 2007

XTL Biopharm Ltd

NOTICE OF SCHEDULE 13G FILING WITH THE US SEC


   NOTICE OF SCHEDULE 13G FILING WITH THE UNITED STATES SECURITIES EXCHANGE    
                                  COMMISSION                                   

Valley Cottage, New York, September 19, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) hereby notifies that it has just become
aware that on September 18, 2007, a Schedule 13G Filing was made with the
United States Securities Exchange Commission ("US SEC") regarding notification
of a 7.89% beneficial ownership of the Company's Ordinary Shares.

The filing can be found on the US SEC's EDGAR website at http://www.sec.gov/
Archives/edgar/data/1023549/000119380507002410/e602614_13g-xtlbio.txt

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-(845)-267-0707 ext. 225